Convalescent Plasma Therapy: a Possible Treatment of COVID-19 Pandemic
Shubha Devi Sapkota¹, Monika Sharma², Gehendra Bhusal³

ABSTRACT

COVID 19 is a newly recognized infectious disease that has rapidly spread with no verified treatment available. It is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2). In Convalescent plasma therapy, the yellowish liquid or the plasma from the recovered blood is used to treat the patient suffering from the same illness. For more than 100 years it has been used to treat severe infections with varying degrees of success. For this present infection, multiple clinical trials on plasma therapy are still under vigorous investigations. Despite the very low chance of risks like allergies, lung damage, and transmission of blood-related infection, the therapy has shown a positive result in the recovery of the patients. Many experts are observing its use as a “stopgap measure” until effective vaccines and antiviral drugs are available in a wide range. However, the main challenges faced are finding suitable donors, its expensiveness in the whole procedure, and inability to perform on a large scale. In this commentary, summarization of the convalescent plasma therapy is done as a hopeful alternative therapy of severe or critical COVID 19. It has also emphasized the promising results shown since the past while the use of this therapy in various infectious diseases.

Keywords: Convalescent Plasma Therapy, Treatment of COVID-19, Pandemic in Nepal

Author Info:
¹NPI-Narayani Samudayik Hospital, College of Nursing, Purbanchal University, Chitwan, Nepal
²Padmashree School of Public Health, Rajiv Gandhi University of Health Science, Karnataka, India
³Chitwan Medical College, Tribhuvan University, Chitwan, Nepal

*Corresponding Author:
Ms. Shubha Sapkota
Email/Contact: shubhasapkota@gmail.com
09779845500500
ORCiD: https://orcid.org/0000-0001-8115-8042

How to cite this article in Vancouver Style?


Disclaimer

Conflict of Interest: None Declared; Source of Support: Nil

Copyright: © 2020 by author(s). This is an open access article distributed under the terms of the Creative Commons Attribution International License 4.0 (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Publisher’s Note

The Europasian Journal of Medical Sciences (EJMS) (www.europasianjournals.org) is an official Journal of Nirvana Psychosocial Care Center & Research Institute (www.nirvanapscrc.com). The Journal as well as publisher remain neutral with regards to any jurisdictional claims in any published articles, its contents and the institutional affiliations of the authors.
BACKGROUND

The world seems to be vulnerable in the face of the COVID-19 pandemics, with over 8.2 million cases already and over 445,000 deaths till June 19, 2020. Scientists all around the globe are working conscientiously to develop the preventable vaccine and to determine the efficacy of many drugs currently available including antivirals, protease inhibitors, nucleotide analog, and interleukin inhibitors. Apart from these, convalescent plasma transfusion is another treatment modality under investigation for its efficacy while treating severe patients.

MAIN TEXT

Convalescent plasma therapy is an experimental treatment modality that uses antibodies found in the bloodstream of the people who’ve recovered from infection for treating infected patients. In this phenomenon, the serum is separated from the blood drawn from the recovered person and screened for virus-neutralizing antibodies.

Previously in the late 1800s, the convalescent blood product was used to treat infectious disease, firstly in treating diphtheria. Meanwhile in 1918-1920 during the Spanish influenza pandemic, the therapeutic regimen was studied. Later it was used widely to treat different infectious diseases like pneumococcal pneumonia and scarlet fever by the 1930s. Although, by the middle of the 20th century, with the development of antimicrobials, its use declined. Whenever new epidemics or pandemics emerge, the use of passive antibody therapy has been renewed e.g., in previous corona virus outbreaks like SARS in 2002-04 and MERS in 2012. These positive results guided WHO in publishing guidelines on the use of the treatment modality for the Ebola virus. Simultaneously, the treatment results have shown a progressive decline in mortality of patients with severe pandemic influenza A virus (H1N1 2009). Even so, exact clinical evidence exhibiting the efficacy of the therapy is scanty.

During the current pandemic, in China, two small studies were done using convalescent plasma therapy, one an uncontrolled case series of five critical patients on mechanical ventilation, and the other, pilot study in ten severe COVID-19 patients. Consequently, the therapy showed sound results with improvement in a clinical outcome like fever, chest pain, cough, and shortness of breathing within 1-3 days of treatment.

Likewise, a randomized clinical trial was performed including 103 patients, standard treatment with convalescent plasma (n=52) against a control group of standard treatment alone (n=51). In this clinically improved result was shown in 28 days with 51.9% in convalescent plasma group vs 43.1% in the standard treatment only group. This trial was terminated early because of the hazard ratio, 1.40, and was not statistically significant.

Furthermore, a study in Texas, USA showed positive results on 25 severe or life-threatening COVID patients who were transfused with convalescent plasma. Gradually by 14th post-transfusion day, there were at least one-point improvement on their clinical status in 19 (76%) patients while 11 of them were discharged. Convalescent plasma therapy if started initially can help discontinue viral shedding and extend the patient’s survival rate in critical COVID-19. Similarly, a decrease in mortality rate was seen in the USA in 5,000 hospitalized patients with severe or life-threatening COVID-19 after convalescent plasma therapy.

The plasma donated by the people who have recovered from COVID-19 having a high concentration of anti-SARS-CoV-2 antibodies determines the success of convalescent plasma therapy. The donor and the patient must have compatible blood types and no signs of multiple diseases, including COVID-19, Hepatitis, and HIV. Many treatment regimens were under trial and few were promising too. Despite that, it might be too early to decide on any result of valid clinical trials. Finding suitable donors and conducting tests to confirm sufficient antibody levels in plasma are likely the main challenges for health care providers. Likewise, blood transfusion reactions, another potential complication is the transmission of unknown pathogens and infection risk to laboratory personnel processing the plasma.

CONCLUSION

Hence, convalescent plasma therapy is considered as a safe treatment option for treating patients with severe COVID-19 disease after different studies showed favoring results. Although, it’s too early to jump to any conclusion so further randomized clinical trials are recommended on a larger scale for its efficacy.

Authors’ contributions: SDS has contributed to conceptualizing and writing of the first draft of the
manuscript. All the authors have put their input in critically reviewing and finalizing the manuscript.

Acknowledgements: We apologize to the authors whose work has not been cited here due to space limitations.

REFERENCES